Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Pegfilgrastim

Review the clinical trials studying pegfilgrastim on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-16 of 16

Gemcitabine Hydrochloride and Cisplatin in Treating Patients with Invasive Bladder Urothelial Cancer
Status: Active
Location: 381 locations
Accelerated or Standard BEP Chemotherapy in Treating Patients with Intermediate or Poor-Risk Metastatic Germ Cell Tumors
Status: Active
Location: 167 locations
A Study of a New Way to Treat Children and Young Adults with a Brain Tumor Called NGGCT
Status: Active
Location: 144 locations
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy before Surgery for Patients with High-Grade Upper Urinary Tract Cancer
Status: Active
Location: 206 locations
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Status: Active
Location: 14 locations
Second-Line Pembrolizumab in Combination with Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Status: Active
Location: 8 locations
Pembrolizumab after Neoadjuvant Chemotherapy followed by Surgery for the Treatment of Patients with Localized, Resectable Pancreatic Cancer
Status: Active
Location: 3 locations
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients with Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Entrectinib for the Treatment of Patients Less Than 3 Years of Age with NTRK1/2/3 or ROS1 Fused High Grade Glioma or Other Central Nervous System Tumor
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Circulating Tumor DNA to Determine Early Switch From First-Line mFOLFIRINOX to Second-Line Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Combination Chemotherapy in Treating Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients with B Acute Lymphoblastic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
PEEL-224 Alone and in Combination with Vincristine and Temozolomide for the Treatment of Refractory, Progressive, or Relapsed Childhood Solid Tumors, Neuroblastoma or Rhabdomyosarcoma
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Venetoclax with Combination Chemotherapy in Treating Patients with Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
gFOLFOXIRITAX Regimen for the Treatment of Locally Advanced or Metastatic Upper Gastrointestinal Adenocarcinoma, I-FLOAT Study
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
MIBG for Refractory Neuroblastoma and Pheochromocytoma
Status: Temporarily Closed to Accrual
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota